Tetraphase Pharmaceuticals Inc(TTPH)stock report

Tetraphase Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company uses its chemistry technology to create antibiotics for multidrug-resistant infections. The Company is developing its lead product candidate, eravacycline, a fully synthetic tetracycline derivative, as a spectrum intravenous (IV) and oral antibiotic for use as a first-line empiric monotherapy for the treatment of multidrug-resistant infections, including multidrug-resistant gram-negative infections. The Company also develops TP-6076 for multidrug-resistant gram-negative infections. Eravacycline is a fluorocycline antibiotic. The Company is conducting a global Phase III clinical program for eravacycline called Investigating Gram-Negative Infections Treated with Eravacycline (IGNITE). TP-271 is a fully synthetic fluorocycline being developed for respiratory disease caused by bacterial biothreat pathogens in healthy volunteers.

Market Cap:9.1M; Shares Outstanding:3.0M; Q3 2019(9/30/19): Cash 24.51M. Loss 16.3M

EPS and Sales:

Date EPS % last year % last quarter
2018.12.31 -1.37 47.91% 92.95%
2019.3.31 -0.36 14.29% 73.72%
2019.6.30 -0.79 -31.67% -119.44%
2019.9.30 -21.7 -11.63% -2646.84%


Date Sales % last year % last quarter
2018.12.31 18.9M 95.57% 29.27%
2019.3.31 1.27M -32.68% -93.28%
2019.6.30 2.35M -82.58% 85.04%
2019.9.30 5.69M -61.11% 142.13%


Insider Transactions:

Institution Ownership:

Total institutions: 71,no change
Shares hold: 514.3k shares. no change
shares% hold: 17.05%,no change

Analyst Ratings:

Leave a Reply